King George’s Medical University (KGMU) has submitted the report of its internal inquiry into the alleged ₹2.5 crore medicine procurement scam that surfaced in the institution’s Urology Department. The report submitted to the university administration is expected to pave the way for disciplinary and legal action against those found responsible.
The scam came to light after officials noticed an unusual rise in expenditure on medicines under the government’s Asadhya Yojana, a scheme meant to provide free treatment to economically weaker patients suffering from serious illnesses. According to the investigation, monthly medicine purchases in the department jumped from around ₹10 lakh to nearly ₹40 lakh in February and over ₹45 lakh in March triggering suspicions of financial irregularities.
A five-member committee constituted by the university examined medicine purchase records, prescriptions and patient data. The inquiry reportedly found discrepancies in the procurement and distribution of costly medicines including instances where drugs were allegedly shown as issued to patients who were either not admitted or did not require such treatment. Investigators also found records suggesting repeated use of expensive injections that are normally administered only once in several months. Earlier KGMU had announced plans to lodge an FIR against four employees allegedly involved in the irregularities. The university had also removed certain contractual staff from their duties and initiated departmental action while the probe was underway.
The controversy has already led to administrative action within the institution. A pharmacist was suspended, criminal proceedings were recommended and officials linked to the department faced scrutiny over alleged negligence and lapses in supervision. With the inquiry report now submitted, university authorities are expected to review its findings and decide on further disciplinary, financial recovery and legal measures. The case has raised serious concerns about oversight mechanisms governing the procurement and distribution of expensive medicines under government-funded healthcare schemes.
